Efficacy and safety of maintenance immune checkpoint inhibitors with or without pemetrexed in advanced non-squamous non-small cell lung cancer: a retrospective study

BACKGROUND: Advanced non-squamous non-small cell lung cancer (NS-NSCLC) patients without driver gene mutations are usually treated with immune checkpoint inhibitors (ICIs) plus pemetrexed as maintenance therapy after first-line ICIs plus 4–6 cycles of pemetrexed/platinum. Some patients in the real w...

Descripción completa

Detalles Bibliográficos
Autores principales: Gu, Xiaodong, Shi, Zhiyong, Shao, Lan, Zhang, Yuxin, Zhang, Yiping, Song, Zhengbo, Wang, Wenxian, Lou, Guangyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128194/
https://www.ncbi.nlm.nih.gov/pubmed/35606756
http://dx.doi.org/10.1186/s12885-022-09674-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128194/
https://www.ncbi.nlm.nih.gov/pubmed/35606756
http://dx.doi.org/10.1186/s12885-022-09674-2

Ejemplares similares